Dutch pharmaceutical and chemicals groups Akzo Nobel and Solvay have taken a step forward in resolving US antitrust action involving price-fixing in the US hydrogen peroxide market by the former and in sodium perborate for the latter firm. Akzo has pleaded guilty to the US Department of Justice and agreed to pay a fine of $32.0 million and Solvay $41.0 million. The DoJ said price-fixing cartels have affected nearly $350.0 million in US commerce from 1998 to 2001.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze